Basit öğe kaydını göster

dc.contributor.authorTemel, İsmail
dc.contributor.authorArmutcu, FERAH
dc.contributor.authorKaplan, S
dc.contributor.authorYildirim, Z
dc.contributor.authorSogut, S
dc.contributor.authorOzyurt, H
dc.contributor.authorKart, L
dc.contributor.authorIraz, M
dc.contributor.authorAkyol, O
dc.contributor.authorOzen, S
dc.date.accessioned2021-03-03T08:10:13Z
dc.date.available2021-03-03T08:10:13Z
dc.identifier.citationSogut S., Ozyurt H., Armutcu F., Kart L., Iraz M., Akyol O., Ozen S., Kaplan S., Temel İ., Yildirim Z., "Erdosteine prevents bleomycin-induced pulmonary fibrosis in rats", EUROPEAN JOURNAL OF PHARMACOLOGY, cilt.494, ss.213-220, 2004
dc.identifier.issn0014-2999
dc.identifier.othervv_1032021
dc.identifier.otherav_160d5c4b-0b40-4225-bcc7-80d0e6ad9f40
dc.identifier.urihttp://hdl.handle.net/20.500.12627/20180
dc.identifier.urihttps://doi.org/10.1016/j.ejphar.2004.04.045
dc.description.abstractOxidative stress plays an important role in the pathogenesis of idiopathic pulmonary fibrosis. Therefore, erdosteine, an antioxidant, is expected to have an inhibitor potential against the disease. Rats were given one dose of bleomycin in pulmonary fibrosis groups and saline in controls. The first dose of oral erdosteine (10 mg/kg/day) was given 2 days before the bleomycin injection to achieve the plateau level in blood and continued until killing. At day 14, fibrotic changes were evaluated, using Aschoft's criteria and lung hydroxyproline content. Bleomycin produced a fivefold increase in fibrosis score that was decreased by 87% by erdosteine (P>0.001) and almost twofold increases in hydroxyproline content which were completely prevented by erdosteine. Myeloperoxidase activities and MDA levels, which were significantly higher in the bleomycin group, were then significantly attenuated by erdosteine. These results revealed that oral erdosteine may prevent the development of acute pulmonary inflammation caused by bleomycin injection via the repression of neutrophil accumulation and lipid peroxidation, resulting in the inhibition of subsequent lung fibrosis. (C) 2004 Elsevier B.V. All rights reserved.
dc.language.isoeng
dc.subjectTemel Bilimler
dc.subjectEczacılık
dc.subjectYaşam Bilimleri
dc.subjectTemel Eczacılık Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.titleErdosteine prevents bleomycin-induced pulmonary fibrosis in rats
dc.typeMakale
dc.relation.journalEUROPEAN JOURNAL OF PHARMACOLOGY
dc.contributor.department, ,
dc.identifier.volume494
dc.identifier.startpage213
dc.identifier.endpage220
dc.contributor.firstauthorID94951


Bu öğenin dosyaları:

DosyalarBoyutBiçimGöster

Bu öğe ile ilişkili dosya yok.

Bu öğe aşağıdaki koleksiyon(lar)da görünmektedir.

Basit öğe kaydını göster